Association of EGFR Exon 19 Deletion and Mirna Expression in Lung Adenocarcinomas.

Lixia Ju,Caicun Zhou
DOI: https://doi.org/10.1200/jco.2014.32.15_suppl.e19140
IF: 45.3
2014-01-01
Journal of Clinical Oncology
Abstract:e19140 Background: Epidermal growth factor receptor (EGFR) is frequently found to be activated by mutation in lung cancer. Though most patients with EGFR activating mutation response to EGFR-TKI, there are still about 30% patients showing no response. MiRNA expression is dysregulated in lung cancer, and miRNAs can regulate EGFR. So it is important to predict the candidate miRNAs that target EGFR mutation and to investigate the availability of these candidate miRNA regulators in lung cancer. Methods: In this study, we investigated the difference of miRNA expression in lung adenocarcinomas cell lines with EGFR exon 19 E746_A750 deletion (H1650 and PC-9) and wild-type EGFR (H1299 and A549) using the Phalanx Human Whole Genome Microarray. Then the expression of individual miRNAs were validated by RT-PCR assays. At last we detected the individual miRNAs expression in tumors of lung adenocarcinoma patients. Results: 1,732 miRNAs was evaluated. We found that miRNAs expression were different between these two groups. hsa-miR-141-3p, hsa-miR-200c-3p, hsa-miR-203, hsa-miR-3182, hsa-miR-934 were upregulated and hsa-miR-4450 were downregulated in the mutated EGFR group. Then they were validated by RT-PCR assays. In 6 tumors with wild-type EGFR and 5 tumors with exon 19 deletion, RT-PCR assays show that hsa-miR-141-3p and hsa-miR-203 upregulated in the mutation group. Conclusions: It is suggested that there are different carcinogenic pathways for EGFR mutation tumors. Those miRNAs that associated EGFR mutation can be further explored for their application in target therapy and prognostics.
What problem does this paper attempt to address?